Citation

Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. Drug Discov. Today 2016; 21(4): 648-653.

Affiliation

Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, USA. Electronic address: weida.tong@fda.hhs.gov.

Copyright

(Copyright © 2016, Elsevier Publishing)

DOI

10.1016/j.drudis.2016.02.015

PMID

26948801

Abstract

This paper provides the largest, revised drug reference list annotated and ranked by the risk for developing hepatotoxicity in humans (DILIrank). We created the new DILIrank list by complementing the previously used drug-labeling information together with existing evidence of clinical causality assessments. High-throughput methods are powerful tools to develop predictive models for assessing drug-induced liver injury (DILI). However, the development of predictive models requires a drug reference list with an accurate annotation of DILI risk in humans. We previously developed a DILI annotation schema based on information curated from the US Food and Drug Administration (FDA)-approved drug labeling for 287 drugs. In this article, we refine the schema by weighing the evidence of causality (i.e., a verification process to evaluate a drug as the cause of DILI) and generate a data set that ranks the DILI risk (DILIrank) in humans for 1036 FDA-approved drugs, providing the largest annotated data set of such drugs in the public domain.

Copyright © 2016. Published by Elsevier Ltd.

Language: en